Get to know our clinical trials

Ensayo del MCLA-128, un anticuerpo IgG1 biespecífico y completo especialmente dirigido a los HER2 y HER3 en pacientes con tumores sólidos

THE MAIN GOAL OF THIS TRIAL IS TO TEST THE SAFETY OF THE MCLA-128 TRIAL DRUG IN PATIENTS WITH SOLID (EPITHELIAL-TYPE) TUMORS LIKE YOURS AND TO SEE WHAT EFFECTS IT HAS ON PATIENTS AND THEIR CANCER.

Navarre headquarters
Madrid headquarters
Status
In recruitment
headquarters
Pamplona

Technical Summary

  • PHASE I/II STUDY OF MCLA-128, A BISPECIFIC, COMPREHENSIVE IGG1 ANTIBODY SPECIFICALLY TARGETING HER2 AND HER3 IN PATIENTS WITH SOLID TUMORS.
  • Code EudraCT: 2014-003277-42
  • Protocol number: MCLA-128-CL01
  • Promoter: Merus N.V.
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

More information about this clinical trial

Information offered by the Spanish Registry of Clinical Studies

  • Summary
  • Information
  • Calendar
  • Headquarters
  • Drugs

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.